Stocklytics Platform
Asset logo for symbol TARS
Tarsus Pharmaceuticals
TARS60
$49.97arrow_drop_down0.12%-$0.06
High Growth
Asset logo for symbol TARS
TARS60

$49.97

arrow_drop_down0.12%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Tarsus Pharmaceuticals (TARS) Stocklytics Forecast

Investors are eager to know the future outlook for Tarsus Pharmaceuticals Inc (TARS) and its stock price. As a leading biopharmaceutical company, Tarsus Pharmaceuticals focuses on developing innovative therapeutics to address various eye disorders. The company has gained significant attention in the market, leaving investors curious about its future prospects. Analysts have been working on price predictions and forecasts for Tarsus Pharmaceuticals Inc (TARS) to provide insights into the stock's potential performance.
Looking ahead to 2023, Tarsus Pharmaceuticals Inc (TARS) is expected to experience considerable growth. Based on AI and machine learning predictions, the stock price is anticipated to rise steadily during this period. With the growing demand for effective eye disorder treatments, Tarsus Pharmaceuticals has positioned itself as a key player in the market. This, combined with the company's ongoing research and development efforts, suggests a positive outlook for its stock price over the forecasted period.
add Tarsus Pharmaceuticals  to watchlist

Keep an eye on Tarsus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Tarsus Pharmaceuticals (TARS) stock?

Analysts have set a target price of $44.83 for Tarsus Pharmaceuticals (TARS), based on forecasts from 12 analysts. The predicted price range extends from a high of $65 to a low of $19. This represents a potential increase of up to 30.08% and a decrease of -61.98% from the current price of $49.97. These forecasts are as of 2020 Nov 10.
help

What are the analyst ratings for Tarsus Pharmaceuticals (TARS) stock?

The analyst ratings for Tarsus Pharmaceuticals (TARS) are distributed as follows: 7 analysts recommend buying, 1 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 8 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Tarsus Pharmaceuticals .
help

What is the AI price prediction for Tarsus Pharmaceuticals (TARS) stock?

At present, there is no AI or machine-learning-based price prediction available for Tarsus Pharmaceuticals (TARS) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level